- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CURANEX PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 17.08. | Curanex Pharmaceuticals Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 21.07. | Curanex Pharmaceuticals Inc - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 14.05. | Curanex Pharmaceuticals Inc: Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission | 235 | GlobeNewswire (Europe) | Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated... ► Artikel lesen | |
| 14.05. | Curanex Pharmaceuticals Inc - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.05. | Curanex Pharmaceuticals Inc - 8-K, Current Report | - | SEC Filings | ||
| 08.04. | Curanex Pharmaceuticals Inc: Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline | 280 | GlobeNewswire (Europe) | Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease According to patient accounts, multiple critically... ► Artikel lesen | |
| 08.04. | EXCLUSIVE: Penny Stock Curanex Expands Cachexia Focus Backed By Patient Recovery Narratives | 1 | Benzinga.com | ||
| 06.04. | Curanex Pharmaceuticals Inc: Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care | 1 | GlobeNewswire (USA) | ||
| 06.04. | EXCLUSIVE: Curanex Highlights Case Study Supporting Cachexia Focus In Oncology Strategy | 1 | Benzinga.com | ||
| 02.04. | Curanex Pharmaceuticals Inc: Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company's Evolution Into a Broader Therapeutics Development ... | 386 | GlobeNewswire (Europe) | Company expands strategic focus into one of oncology's most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) ("Curanex"... ► Artikel lesen | |
| 02.04. | EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases | 2 | Benzinga.com | ||
| 02.04. | Curanex Pharmaceuticals Inc - 8-K, Current Report | 2 | SEC Filings | ||
| 30.03. | Curanex Pharmaceuticals Inc: Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission | 467 | GlobeNewswire (Europe) | Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform Jericho, New York, March 30, 2026 (GLOBE NEWSWIRE) -- Curanex... ► Artikel lesen | |
| 30.03. | Curanex Pharmaceuticals Inc - 10-K, Annual Report | - | SEC Filings | ||
| 18.03. | Curanex Pharmaceuticals Inc: Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission | 264 | GlobeNewswire (Europe) | Phyto-N 28-Day Repeat-Dose Study in Rats and Dogs Shows No Findings of Toxicological Significance at Maximum Feasible Dose, Enabling Advancement to GLP Toxicology Program Jericho, New York, March... ► Artikel lesen | |
| 12.03. | Curanex stärkt wissenschaftlichen Beirat vor wichtigem Zulassungsantrag | - | Investing.com Deutsch | ||
| 12.03. | Curanex adds two advisors to scientific board ahead of IND filing | 1 | Investing.com | ||
| 12.03. | Curanex Pharmaceuticals Inc: Curanex Expands Scientific Advisory Board With Two Distinguished Researchers | 1 | GlobeNewswire (USA) | ||
| 11.03. | Curanex adds two pharmaceutical veterans to advisory board | 2 | Investing.com | ||
| 11.03. | Curanex Pharmaceuticals Inc: Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CANOPY GROWTH | 0,897 | -0,95 % | Canopy Growth Corporation: Canopy Growth Secures Renewed EU GMP Certification at Kincardine as European Medical Cannabis Business Grows | Renewed certification maintains Kincardine's role in Canopy Growth's EU GMP flower supply chain
Canopy Growth Corporation ("Canopy Growth", "our", "we" or the "Company") (TSX: WEED) (Nasdaq: CGC)... ► Artikel lesen | |
| EYEPOINT | 4,240 | +0,95 % | XFRA PV3B: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,826 | +3,51 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update | AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| COMPASS PATHWAYS | 12,200 | 0,00 % | Vergiss Zulassungen! Wer zahlt für die Therapie? Diese 3 Biotech-Aktien zeigen, worauf es jetzt wirklich ankommt | ||
| CORBUS PHARMACEUTICALS | 9,130 | 0,00 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer | NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage company focused on developing promising new therapies... ► Artikel lesen | |
| DARE BIOSCIENCE | 0,801 | 0,00 % | Daré Bioscience, Inc.: DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 "50 Over 50: Innovation" List | ||
| CITIUS PHARMACEUTICALS | 0,575 | 0,00 % | Citius Pharmaceuticals, Inc. - 8-K, Current Report | ||
| ELEDON PHARMACEUTICALS | 2,860 | -2,05 % | Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026 Long-term Phase 2 BESTOW data presented... ► Artikel lesen | |
| EXICURE | 0,985 | -1,50 % | Exicure, Inc.: Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance | WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company") today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics... ► Artikel lesen | |
| CHINA SXT PHARMACEUTICALS | 3,210 | -1,53 % | XFRA NEW INSTRUMENTS AVAILABLE ON 10.08.2026 | The following instruments on XETRA do have their first trading 10.08.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 10.08.2026
Aktien
1 KYG472811036 IMC Rare Earths Ltd.
2... ► Artikel lesen | |
| COSMOS HEALTH | 0,175 | -0,63 % | Cosmos Health Inc.: Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18 Across the U.S. Cardiovascular Health and Antioxidant Categories | CHICAGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it is projecting... ► Artikel lesen | |
| CUMBERLAND PHARMACEUTICALS | 7,930 | +1,15 % | Cumberland Pharmaceuticals Inc.: Cumberland Pharmaceuticals Reports Company Update & Q2 2026 Financial Results | $100 million Strategic Transaction Closed
Special Shareholder Dividend Funded
Advancing Late Stage Clinical Pipeline
NASHVILLE, Tenn., Aug. 4, 2026 /PRNewswire/... ► Artikel lesen | |
| CHAMPIONS ONCOLOGY | 4,320 | +1,41 % | Champions Oncology, Inc.: Champions Oncology Reports Record Annual Revenue of $59 Million | Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA HACKENSACK, NJ / ACCESS Newswire / July 27, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology... ► Artikel lesen | |
| CDT EQUITY | 2,500 | +0,40 % | XFRA ZK70: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCDT EQ. NEW 2026... ► Artikel lesen | |
| DATAMEDS AI | 1,300 | 0,00 % | DataMEDS AI reports Q2 results |
CURANEX PHARMACEUTICALS INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -1,89 % bei einem Aktienkurs von 4,670 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CURANEX PHARMACEUTICALS INC finden Sie auf Wallstreet Online.